- Home
- AGL vs CNSP Comparison
AGL vs CNSP Comparison
Compare AGL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | CNSP |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AGL | CNSP |
|---|---|---|
| Price | $80.72 | $5.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $55.68 | $20.00 |
| AVG Volume (30 Days) | 555.5K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $5,932,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $30.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.73 |
| 52 Week High | $90.48 | $10.59 |
Technical Indicators
Market Signals| Indicator | AGL | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 78.35 | 56.07 |
| Support Level | $0.63 | $2.01 |
| Resistance Level | N/A | $8.56 |
| Average True Range (ATR) | 8.71 | 1.04 |
| MACD | 3.52 | -0.16 |
| Stochastic Oscillator | 87.14 | 34.95 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.